Contribute Try STAT+ Today

Dr. Elizabeth Nabel, president of Brigham and Women’s Hospital, said Thursday she was resigning from Moderna’s board of directors after the Globe inquired about whether her role at the Cambridge biotech company was a conflict of interest with her hospital’s participation in a large study of Moderna’s experimental COVID-19 vaccine that just got underway.

The hospital said in a statement Thursday that when Nabel joined Moderna’s board in 2015, Brigham and Women’s parent company put several guardrails in place to prevent a conflict of interest. More safeguards were imposed when the hospital was named one of 87 clinical sites for the late-stage trial trial that began Monday, it said. The study is being led partly by a Brigham infectious diseases specialist, who also is helping to run the nationwide testing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.